Latest Conference Coverage

A retrospective observation study presented as a poster at the 2022 AES annual meeting revealed that youth with focal epilepsy were more at risk for suicidal ideation when there is a delay in receiving a diagnosis.

Data from the Pediatric Epilepsy Learning Healthcare System suggest that a variety of factors—including age, preference, insurance, and demographics—affect physician selection of antiseizure medications, with little standardization among this population.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Epilepsy Society.

The associate clinical professor of neurology at OSU Wexner Medical Center discussed the state of interdisciplinary care for individuals with epilepsy, and how these care teams operate. [WATCH TIME: 2 minutes]

Data from the BUTTERFLY study of 36 children with Dravet syndrome have provided 12-month measurements of neurodevelopment, clinical status, quality of life, and executive function. Investigators expressed that these data will help inform future trial outcome measures.

Zachary Grinspan, MD, MS, a pediatric epilepsy specialist at Weill Cornell Medicine, in New York City, spoke about the analysis of large amounts of data on pediatric epilepsy at the 2022 American Epilepsy Society Annual Meeting.

The professor of neurology at NYU Grossman School of Medicine and chief medical officer of the Epilepsy Foundation discussed the critical need to ensure the proper classification of seizures when enrolling patients in clinical trials. [WATCH TIME: 4 minutes]

The behavioral neurologist at the Barrow Neurological Institute provided perspective on the safety profile of lecanemab and the importance of a low incidence of amyloid-related imaging abnormalities. [WATCH TIME: 3 minutes]

Over a 12-week treatment period, investigators found no significant differences in mean Cohen Mansfield Agitation Inventory scores between mirtazapine and placebo, with similar rates in adverse events.

Across 3 trials in patients with Alzheimer disease agitation, brexpiprazole doses of 2 or 3 mg/day was safe and showed a statistically significant improvement vs placebo in agitation.

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the treatment differences and unmet needs between dementia with Lewy bodies and Alzheimer disease. [WATCH TIME: 4 minutes]

The senior research scientist at the Institute for Systems Biology spoke about his presentation on multimodal clinical and lifestyle interventions that improve cognitive outcomes at the 2022 CTAD conference. [WATCH TIME: 4 minutes]

Over a 12-week treatment period, irsenontrine was well tolerated across both amyloid positive and negative patients, with no significant difference in pharmacodynamic responses or change in central nervous system biomarkers.

The president and chief executive officer of INmune Bio detailed the mechanistic advantages of XPro1595 as a potentially therapeutic benefit for patients with Alzheimer disease and dementia. [WATCH TIME: 5 minutes]

Over a 6-month period, percent change and mean change in brain amyloid levels significantly favored donanemab over aducanumab (Aduhelm; Biogen).

An ongoing phase 1b/2a clinical trial showed that both the ACI-35.030 and JACI-35.054 vaccines are safe as a treatment for patients in the earlier stages of Alzheimer disease, the authors suggested ACI-35.030 suggested as the superior vaccine candidate.

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided background on incorporation of real-world methods to optimize treatment selection for multiple sclerosis.

In the pivotal phase 3 Clarity AD trial, lecanemab (Biogen) demonstrated significant impacts on primary and secondary end points, with additional promising results on biomarker analyses and safety.

The postdoctoral researcher and health psychologist at King's College London spoke at ECTRIMS 2022 about the digital approach to treating fatigue in multiple sclerosis and the lack of available measurements. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

The postdoctoral researcher and health psychologist at King's College, London spoke at ECTRIMS 2022 about the relationship between mood and fatigue in patients with MS. [WATCH TIME: 2 minutes]

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided perspective on how the clinical community can improve trials for multiple sclerosis that help improve treatment decisions. [WATCH TIME: 4 minutes]

The postdoctoral researcher and health psychologist at King's College, London spoke at ECTRIMS 2022 about the most important aspect for improving fatigue in MS. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke at ECTRIMS 2022 about the difference in conversation for therapies between pediatric patients and adult patients with MS. [WATCH TIME: 5 minutes]

Darina Petrovsky, PhD, RN, assistant professor, Rutgers University, spoke about her current study focused on developing a music-based application for people with dementia and their caregivers who have trouble sleeping.

The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke at ECTRIMS 2022 about how her patients with pediatric MS have been inspirational to her in her practice. [WATCH TIME: 4 minutes]

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine detailed the next steps in reforming and applying new 2-stage models that improve selection for MS disease-modifying therapies. [WATCH TIME: 6 minutes]